PMID- 12670740
OWN - NLM
STAT- MEDLINE
DCOM- 20031216
LR  - 20240109
IS  - 1043-2760 (Print)
IS  - 1043-2760 (Linking)
VI  - 14
IP  - 3
DP  - 2003 Apr
TI  - The adipocyte in insulin resistance: key molecules and the impact of the 
      thiazolidinediones.
PG  - 137-45
AB  - Globally, the prevalence of obesity is escalating, and insulin resistance 
      resulting from increased (predominantly visceral) adipose tissue mass has been 
      identified as a key factor that could drive parallel rises in type 2 diabetes 
      mellitus (T2DM) prevalence. Correlations between these global epidemics have 
      encouraged investigation into potential molecular links between the related 
      impairments in lipid and glucose homeostasis. This article reviews factors 
      released from adipose tissue that could contribute to the development of insulin 
      resistance and beta-cell dysfunction, including tumour necrosis factor alpha 
      (TNF-alpha), free fatty acids (FFAs), adiponectin, resistin and leptin. It also 
      considers whether agonists of the peroxisome proliferator-activated receptor 
      gamma, which is abundant in adipose tissue, might have an important impact on 
      factors associated with adipocyte metabolism. For example, the 
      thiazolidinediones, a class of oral anti-diabetic agents that reduce insulin 
      resistance and improve beta-cell function, might mediate these effects by 
      regulating adipocyte-derived factors, in particular TNF-alpha and FFAs.
FAU - Arner, Peter
AU  - Arner P
AD  - Dept of Medicine, CME M63, Huddinge University Hospital, Stockholm, Sweden. 
      peter.arner@medhs.ki.se
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Trends Endocrinol Metab
JT  - Trends in endocrinology and metabolism: TEM
JID - 9001516
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Leptin)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Adipocytes/drug effects/*physiology
MH  - Animals
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology
MH  - Insulin Resistance/*physiology
MH  - Islets of Langerhans/drug effects/physiopathology
MH  - Leptin/physiology
MH  - Obesity/physiopathology
MH  - Receptors, Cytoplasmic and Nuclear/*drug effects
MH  - Species Specificity
MH  - Thiazolidinediones/*pharmacology
MH  - Transcription Factors/*drug effects
RF  - 65
EDAT- 2003/04/03 05:00
MHDA- 2003/12/17 05:00
CRDT- 2003/04/03 05:00
PHST- 2003/04/03 05:00 [pubmed]
PHST- 2003/12/17 05:00 [medline]
PHST- 2003/04/03 05:00 [entrez]
AID - S1043276003000249 [pii]
AID - 10.1016/s1043-2760(03)00024-9 [doi]
PST - ppublish
SO  - Trends Endocrinol Metab. 2003 Apr;14(3):137-45. doi: 
      10.1016/s1043-2760(03)00024-9.